Radiation Oncologist Speaks to AI Potential in the Cancer Space

News
Video

Richard Bakst, MD, speaks to the potential use of artificial intelligence in the radiation oncology space, and how he hopes to see it evolve.

In the field of radiation oncology, artificial intelligence (AI) has emerged as a transformative force, that can help to redefine diagnostic and therapeutic approaches. In an interview with CancerNetwork®, Richard Bakst, MD, discussed the impact of AI in radiology, and how it has the potential to enhance patient care and medical practices.

Bakst, a radiation oncologist at Mount Sinai, highlighted AI's influence in diagnostic radiology, particularly in screening for lung cancer and assisting in demographic interpretations. He also mentioned AI's budding role in therapeutic radiology; its ability to detect microscopic disease on imaging scans and assist in contouring normal structures shows promise for optimizing treatment planning.

Looking toward the future, Bakst believes AI will become a valuable tool in radiotherapy, influencing volume design, assessing the risk of microscopic disease, and aiding in tumor volume elimination. This integration of AI is expected to significantly enhance the precision and effectiveness of cancer treatment.

With AI's ability to detect subtle abnormalities, optimize treatment planning, and enhance targeting precision, it is poised to influence the radiology space.

Transcript:

[AI] is taking a role in all spaces. It has a huge footprint in diagnostic radiology, screening for lung cancer, and assisting in demographic reads; [it has] a very strong foothold in the diagnostic space. It’s going to make its way into therapy space, and it already has in some instances in terms of our workflow. We have the ability to use AI to detect microscopic disease on our scans. [This helps] think about contouring normal structures. It will penetrate the therapeutic planning for radiotherapy. Definitely in the very short term, hopefully it will influence our volume design, assess the risk of microscopic disease, and help eliminate tumor volumes. It’s coming. It will enhance our ability to target cancer, risk stratify patients, and determine appropriate volumes.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Related Content